Edwards Lifesciences (NYSE:EW) Updates Q1 2025 Earnings Guidance

Edwards Lifesciences (NYSE:EW) updated its first quarter 2025 earnings guidance on Tuesday. The company provided earnings per share guidance of 0.580-0.640 for the period, compared to the consensus earnings per share estimate of 0.590. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion. Edwards Lifesciences also updated its FY 2025 guidance to 2.400-2.500 EPS.

Edwards Lifesciences Stock Performance

EW stock traded up $4.03 during trading hours on Wednesday, hitting $74.94. 1,236,718 shares of the stock were exchanged, compared to its average volume of 4,270,121. Edwards Lifesciences has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $44.20 billion, a P/E ratio of 10.80, a P/E/G ratio of 3.64 and a beta of 1.10. The company has a 50-day simple moving average of $72.47 and a two-hundred day simple moving average of $69.32.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. On average, analysts forecast that Edwards Lifesciences will post 2.56 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

EW has been the subject of a number of research analyst reports. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their price target for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Canaccord Genuity Group boosted their target price on Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a research note on Thursday, December 5th. Robert W. Baird reduced their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Morgan Stanley increased their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday. Finally, Truist Financial reiterated a “hold” rating and set a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $79.71.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 2,500 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the completion of the sale, the vice president now owns 23,189 shares in the company, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 1.29% of the stock is currently owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.